Compass Therapeutics: Neil Lerner buys 20,000 shares
The 62,500 unvested restricted stock units are subject to service-based vesting, with the first installment set to vest January 2, 2027.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Compass Therapeutics, Inc. (CMPX) Chief Accounting Officer Neil Lerner purchased 20,000 shares of common stock at $0.92 per share on October 1, 2026. The purchase was reported as direct; no Rule 10b5-1 plan is reported. Lerner’s reported holdings after the purchase were 420,000 shares, including 62,500 unvested restricted stock units subject to service-based vesting in four equal annual installments, with the first installment vesting on January 2, 2027.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F1 | 20,000 | $0.92 | $18K |
Footnotes (1)
- F1. 62,500 of the shares represents unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.
Key Figures
Key Terms
restricted stock units financial
service-based vesting conditions financial
four equal annual installments financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the vesting terms for Neil Lerner’s CMPX restricted stock units?
AI-generated analysis. How Rhea-AI works. Not financial advice.